1. Home
  2. LIXT vs SPRC Comparison

LIXT vs SPRC Comparison

Compare LIXT & SPRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LIXT
  • SPRC
  • Stock Information
  • Founded
  • LIXT 2005
  • SPRC 2004
  • Country
  • LIXT United States
  • SPRC Israel
  • Employees
  • LIXT N/A
  • SPRC N/A
  • Industry
  • LIXT Biotechnology: Pharmaceutical Preparations
  • SPRC Biotechnology: Pharmaceutical Preparations
  • Sector
  • LIXT Health Care
  • SPRC Health Care
  • Exchange
  • LIXT Nasdaq
  • SPRC Nasdaq
  • Market Cap
  • LIXT 4.1M
  • SPRC 3.5M
  • IPO Year
  • LIXT N/A
  • SPRC N/A
  • Fundamental
  • Price
  • LIXT $1.24
  • SPRC $0.31
  • Analyst Decision
  • LIXT
  • SPRC
  • Analyst Count
  • LIXT 0
  • SPRC 0
  • Target Price
  • LIXT N/A
  • SPRC N/A
  • AVG Volume (30 Days)
  • LIXT 8.5K
  • SPRC 161.2K
  • Earning Date
  • LIXT 05-08-2025
  • SPRC 02-15-2025
  • Dividend Yield
  • LIXT N/A
  • SPRC N/A
  • EPS Growth
  • LIXT N/A
  • SPRC N/A
  • EPS
  • LIXT N/A
  • SPRC N/A
  • Revenue
  • LIXT N/A
  • SPRC $1,747,000.00
  • Revenue This Year
  • LIXT N/A
  • SPRC N/A
  • Revenue Next Year
  • LIXT N/A
  • SPRC N/A
  • P/E Ratio
  • LIXT N/A
  • SPRC N/A
  • Revenue Growth
  • LIXT N/A
  • SPRC N/A
  • 52 Week Low
  • LIXT $1.02
  • SPRC $0.20
  • 52 Week High
  • LIXT $3.50
  • SPRC $1.79
  • Technical
  • Relative Strength Index (RSI)
  • LIXT 50.56
  • SPRC 54.30
  • Support Level
  • LIXT $1.10
  • SPRC $0.25
  • Resistance Level
  • LIXT $1.35
  • SPRC $0.31
  • Average True Range (ATR)
  • LIXT 0.11
  • SPRC 0.02
  • MACD
  • LIXT 0.02
  • SPRC 0.01
  • Stochastic Oscillator
  • LIXT 62.40
  • SPRC 91.31

About LIXT Lixte Biotechnology Holdings Inc.

Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.

About SPRC SciSparc Ltd.

SciSparc Ltd is a specialty clinical-stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company has two reportable segments; development of drugs based on cannabinoid molecules to be approved by an official regulatory authority (the company's operation); and online sales of a various range of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.

Share on Social Networks: